DAPT (GSI-IX): A Potent γ-Secretase Inhibitor for Notch & APP

Executive Summary: DAPT (GSI-IX) is a selective γ-secretase inhibitor with an IC₅₀ of 115 nM for amyloid-β reduction in mammalian cell lines (source: product_spec). It blocks Notch receptor processing, modulating Notch signaling pathways that regulate cellular differentiation and angiogenesis (source: paper). DAPT is widely utilized in Alzheimer's disease, cancer, and autoimmune disorder research as an experimental probe (source: internal_content). In critical limb ischemia mouse models, DAPT antagonizes pro-angiogenic effects induced by Notch/NF-κB axis activation (source: paper). APExBIO supplies DAPT (SKU A8200), supporting standardized reproducible research (source: product_spec).

Biological Rationale

γ-Secretase is a multi-subunit protease complex responsible for intramembrane cleavage of Notch receptors and amyloid precursor protein (APP). This cleavage generates bioactive peptides such as the Notch intracellular domain and amyloid-β, which regulate differentiation, neurodegeneration, and angiogenesis. Aberrant γ-secretase activity is implicated in Alzheimer's disease, certain cancers, and autoimmune disorders due to dysregulated Notch or amyloidogenic signaling (source: internal_content). DAPT (GSI-IX) enables precise modulation of these pathways for mechanistic and translational studies.

Mechanism of Action of DAPT (GSI-IX)

DAPT (CAS 208255-80-5), also known as LY-374973, is a potent, cell-permeable inhibitor that selectively targets γ-secretase. DAPT binds the presenilin-containing γ-secretase complex, blocking cleavage of Notch and APP (source: product_spec). This results in reduced production of amyloid-β peptides and prevention of Notch intracellular domain release. Inhibition of Notch processing alters downstream gene expression, affecting cellular differentiation, apoptosis, and, in vivo, angiogenesis (source: paper).

Evidence & Benchmarks

• DAPT reduces amyloid-β peptide generation with an IC₅₀ of 115 nM in mammalian cell lines (source: product_spec).
• DAPT inhibits total γ-secretase activity with an IC₅₀ of 200 nM in cellular assays (source: product_spec).
• In SHG-44 human glioma cells, 1.0 μM DAPT inhibits proliferation in a concentration-dependent manner (source: product_spec).
• In critical limb ischemia mouse models, DAPT administration reverses pro-angiogenic effects mediated by Notch/NF-κB signaling, decreasing expression of Ang2, VEGFA, Notch3, and CD31 (source: paper).
• Subcutaneous injection of DAPT at 10 mg/kg/day in mice reduces CD31-positive endothelial cells in tumor tissue, indicating impaired angiogenesis (source: product_spec).
• DAPT is insoluble in water but dissolves at ≥21.62 mg/mL in DMSO and ≥16.36 mg/mL in ethanol with sonication (source: product_spec).

Compared to prior mechanistic reviews, this article provides additional cross-disease application context and protocol granularity for translational labs.

Applications, Limits & Misconceptions

DAPT (GSI-IX) is extensively applied in studies of Alzheimer's disease pathogenesis, cancer biology (particularly Notch-driven tumors), autoimmune disorder models, and angiogenesis research. It is suitable for delineating γ-secretase-dependent signaling and for testing therapeutic hypotheses involving Notch or APP processing. Recent organoid and tissue models, such as hiPSC-derived hepatobiliary organoids, benefit from DAPT to probe developmental signaling (see: organoid study; this article builds on those findings by detailing concentration benchmarks and disease relevance).

Common Pitfalls or Misconceptions

• DAPT does not inhibit all aspartyl proteases; its selectivity is restricted to γ-secretase complexes (source: product_spec).
• It is not effective as a direct therapeutic agent in humans; its use is limited to preclinical and in vitro research (source: workflow_recommendation).
• Long-term storage of DAPT solutions can result in loss of potency; fresh aliquots are advised for reproducibility (source: product_spec).
• Inhibition of Notch signaling can have context-dependent effects, such as impairment of angiogenesis in some models and altered differentiation in others (source: paper).
• DAPT does not reverse established amyloid plaques in animal models; its effect is preventive at the level of peptide generation (source: workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• cell-based γ-secretase inhibition | 1.0 μM | mammalian cell lines (e.g., SHG-44) | Benchmark for Notch/APP pathway modulation in vitro | product_spec
• angiogenesis inhibition (mouse) | 10 mg/kg/day (subcutaneous) | tumor and CLI models | Standard for testing Notch-dependent vascular effects in vivo | paper
• stock solution preparation | ≥21.62 mg/mL (DMSO), ≥16.36 mg/mL (ethanol, sonicated) | all applications | Ensures adequate drug solubility before dilution | product_spec
• storage | -20°C (solid), avoid prolonged solution storage | all applications | Maintains compound integrity and activity | product_spec

Why this cross-domain matters, maturity, and limitations

While DAPT's original use was in neurodegeneration and oncology, its role in modulating angiogenesis via Notch/NF-κB is validated in critical limb ischemia research, demonstrating cross-domain relevance. However, mechanistic extrapolation to unrelated proteases or direct clinical translation remains unproven (source: paper).

For workflow design, see also this scenario-driven protocol guidance, which this article extends by providing updated numeric benchmarks and cross-disease evidence.

Conclusion & Outlook

DAPT (GSI-IX) remains a gold-standard tool for manipulating γ-secretase-dependent signaling in cell and animal models. Its validated selectivity and potency underpin its widespread adoption in Alzheimer's disease research, cancer research, and angiogenesis studies. Limitations include its restriction to research-only contexts and the necessity for context-aware protocol design. Future progress in Notch and APP pathway therapeutics will continue to rely on robust compounds such as DAPT for target validation and mechanistic dissection (source: paper; product_spec).